{
    "code": "52027639",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027639",
    "time": "2021-03-05 03:12:33",
    "許可證字號": "衛部藥輸字第027639號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/04\/22",
    "發證日期": "108\/04\/22",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202763906",
    "中文品名": "旁必福注射液",
    "英文品名": "Parsabiv Solution for Injection",
    "適應症": "PARSABIV適用於治療罹患慢性腎臟病 (CKD) 且接受血液透析之成人病人的次發性副甲狀腺機能亢進 (secondary HPT)。",
    "劑型": "279注射液",
    "包裝": "2.5mg\/0.5ml、5mg\/ml、10mg\/2ml玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "113\/04\/22",
    "主成分略述": "Etelcalcetide Hydrochloride",
    "限制項目": "02輸　入 5F免除銜接性試驗",
    "申請商名稱": "620117N253  台灣安進藥品有限公司",
    "申請商地址": "臺北市信義區松仁路100號13樓之1、之2",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0030300  Patheon Manufacturing Services LLC",
            "製造廠廠址": "5900 Martin Luther King Jr. Highway,Greenville,NC27834,USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FPR0034000  AMGEN MANUFACTURING,LIMITED",
            "製造廠廠址": "STATE ROAD 31,KM 24.6 JUNCOS,PUERTO RICO 00777-4060",
            "製造廠公司地址": "",
            "製造廠國別": "PUERTO RICO",
            "製程": "包裝"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "8818002000",
            "成分名稱": "Etelcalcetide Hydrochloride",
            "含量描述": "(equivalent to Etelcalcetide......5MG)",
            "含量": "5.7700000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "旁必福注射液_中文仿單-108-12-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=002&Type=9"
        },
        {
            "title": "MCK01360 ART CRTN DP VI 10mg 416 10ct-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=006&Type=8"
        },
        {
            "title": "MCK01359 ART CRTN DP VI 5mg 416 10ct-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=005&Type=8"
        },
        {
            "title": "MCK01358 ART CRTN DP VI 2.5mg 416 10ct-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=004&Type=8"
        },
        {
            "title": "MCK01357 ART LBL VI 10mg 416-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=003&Type=8"
        },
        {
            "title": "MCK01356 ART LBL VI 5mg 416-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=002&Type=8"
        },
        {
            "title": "MCK01355 ART LBL VI 2.5mg 416-108-05-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027639&Seq=001&Type=8"
        }
    ]
}